Here are three updates on GI companies from the past week:
Exact Sciences posted $102.9 million in second quarter 2018 revenue, missing investor predictions by $1.8 million, or 1.7 percent, causing its stock to fall 18.75 percent.
Exact Sciences is sponsoring Fight Colorectal Cancer and PGA Tour professional Tom Lehman to promote Fight CRC.
RedHill Biopharma's Crohn's disease drug, RHB-104, successfully met its primary and secondary endpoints, achieving remission at 26 weeks.